Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis

Internal Medicine

Volumn 52, Issue 22, 2013, Pages 2495-2501

  Sakamoto, Susumu ^a   Itoh, Takafumi ^a   Muramatsu, Yoko ^a   Satoh, Keita ^a   Ishida, Fumiaki ^a   Sugino, Keishi ^a   Isobe, Kazutoshi ^a   Homma, Sakae ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Advanced stage IPF; N acetylcysteine; Pirfenidone

Indexed keywords

ACETYLCYSTEINE; PIRFENIDONE; PREDNISOLONE; TACROLIMUS;

AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LOW DRUG DOSE; LUNG FUNCTION TEST; MALE; NAUSEA; PHOTOSENSITIVITY DISORDER; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84887573050     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.8498     Document Type: Article

References (15)

1. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idi-opathic pulmonary fibrosis. Eur Respir J 35: 830-835, 2010.
2. Taniguchi H, Kondoh Y, Ebina M, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12: 93, 2011.
3. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047, 2005.
4. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821-829, suppl 12-14, 2010.
5. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377: 1760-1769, 2011.
6. Ragh G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on idiopathic pulmonary fibrosis evidence based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.
7. Japanese Respiratory Society's Committee formulating diagnosis and treatment guideline for diffuse lung diseases. Clinical Diagnostic and Treatment Guidance for Idiopathic Interstitial Pneumonias. Nankodo, Tokyo, 2011: 111-113.
8. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibro-sis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374: 222-228, 2009.
9. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350: 125-133, 2004.
10. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229-2242, 2005.
11. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibro-sis. Am J Respir Crit Care Med 177: 75-81, 2008.
12. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for IPF: randomized placebo controlled trial results. Am J Respir Crit Care Med 181: 604-610, 2010.
13. Hagiwara S, Ishii Y, Kitamura S, et al. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 162: 225-231, 2000.
14. Muramatsu Y, Sugino K, Sato K, et al. Efficacy of inhaled N-acetylcysteine on lung function and redox balance in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183: A1529, 2011.
15. Homma S, Azuma A, Taniguchi H, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 17: 467-477, 2012.